SRRK ▲ +1.3% - Scholar Rock Holding Corporation $SRRK - Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial Scholar Rock rose 1.3% after announcing that the FDA granted Fast Track designation to its apitegromab program for facioscapulohumeral muscular dystrophy, a rare genetic muscle disorder. The designation, which accelerates the regulatory review process, came as the company began dosing patients in its Phase 2 FORGE trial, advancing a program that previously showed potential in treating this severe condition. Fast Track status typically signals FDA confidence in a drug candidate's potential to address unmet medical needs, which investors viewed positively for the biotech's pipeline. 02-SEP-2026 08:08 AM ET